OMND — Optimind Pharma Income Statement
0.000.00%
Last trade - 00:00- CA$1.10m
- CA$1.12m
- CA$0.12m
Annual income statement for Optimind Pharma, fiscal year end - February 29th, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2023 February 28th | 2024 February 29th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.17 | 0.123 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | -0.14 | -0.173 | 0.161 | 3.26 | 1.34 |
| Operating Profit | 0.14 | 0.173 | -0.161 | -3.09 | -1.21 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.025 | 0.131 | -0.172 | -3.09 | -1.41 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.025 | 0.131 | -0.172 | -3.08 | -1.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.025 | 0.131 | -0.172 | -3.08 | -1.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.025 | 0.131 | -0.172 | -3.08 | -1.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.034 | -0.019 | -0.017 | -0.021 | -0.012 |